Top Story

Our latest 2014 update of the Metastatic non-small-cell lung cancer (NSCLC) Clinical Practice Guideline has just been published


E. van Cutsem comments two studies: NAPOLI-1, demonstrating improved survival for met pancreatic cancer patients with the novel drug MM-398; the SPARC analysis of MPACT, showing that the protein cannot be used as predictive marker for gemcitabine + nab-paclitaxel. There is still an unmet need to identify predictive markers for these patients.